Table 1.
Clinicopathological features of the 33 patients.
| Clinicopathological Features | Categories | n (%) | |
|---|---|---|---|
| Sex | Female | 33 (100) | |
| Age | <60 | 14 (42.4) | |
| >60 | 19 (57.6) | ||
| Cutaneous metastases location | Local * | 15 (46.9) | |
| Distance | 17 (53.1) | ||
| NA | 1 | ||
| Menopausal status at diagnosis | Yes | 27 (90) | |
| No | 3 (10) | ||
| NA | 3 | ||
| pT | 1 | 5 (18.5) | |
| 2 | 14 (51.9) | ||
| 3 | 5 (18.5) | ||
| 4 | 3 (11.1) | ||
| NA | 6 ** | ||
| pN | 0 | 8 (30.8) | |
| 1 | 10 (38.5) | ||
| 2 | 2 (7.7) | ||
| 3 | 6 (23) | ||
| NA | 7 ** | ||
| Clinical stage | I | 4 (12.5) | |
| II | 5 (15.6) | ||
| III | 14 (43.7) | ||
| IV | 9 (28.1) | ||
| NA | 1 | ||
| Histological Grade | 1 | 1 (3) | |
| 2 | 13 (39.4) | ||
| 3 | 19 (57.6) | ||
| LIV | Yes | 11 (33.3) | |
| No | 22 (66.7) | ||
| Immunohistochemical markers | ER+ | 19 (57.6) | |
| PR+ | 11 (33.3) | ||
| HER2+ | 5 (15.2) | ||
| Ki67 | ≤15% | 9 (27.3) | |
| 16–29% | 5 (15.2) | ||
| ≥30% | 19 (57.6) | ||
| TN | 12 (36.4) | ||
| Surrogated molecular type | Luminal HER2- | 16 (48.5) | |
| Luminal HER2+ | 3 (9) | ||
| HER2+ (non-luminal) | 2 (6) | ||
* Local lesions refer to lesions that presented on the skin of the breast/thorax. ** Patients diagnosed at stage IV did not undergo surgery and did not have pT and pN data.